Neurology/Neurosurgery
A comparison of clinical outcomes in 39 patients treated with atidarsagene autotemcel, a hematopoietic stem-cell–based gene therapy, with those of untreated patients showed a strong treatment effect over the long term.
In two trials in relapsing multiple sclerosis, tolebrutinib (a brain-penetrant BTK inhibitor) was not superior to teriflunomide at reducing annualized relapse rates.
In this trial involving 543 patients with stroke due to occlusion of medium or distal vessels, endovascular treatment within 24 hours after the onset of symptoms was not effective in improving functional outcome at 90 days.
A 46-year-old woman with a history of migraine with visual aura presented with a 3-hour history of headache, as well as weakness and numbness in the right arm.
1-20 of 3816 results
- A comparison of clinical outcomes in 39 patients treated with atidarsagene autotemcel, a hematopoietic stem-cell–based gene therapy, with those of untreated patients showed a strong treatment effect over the long term.
- As the fossil-fuel industry continues to obstruct efforts to curtail pollution from its products, the health community should use strategies that have been effective in fighting other health-harming industries.
- A 46-year-old woman with a history of migraine with visual aura presented with a 3-hour history of headache, as well as weakness and numbness in the right arm.
- A 54-year-old man presented with a 5-month history of weakness. Examination showed proximal muscle weakness and absent patellar reflexes that briefly reappeared after voluntary muscle contraction (shown in a video).
- In a trial involving patients with ischemic stroke due to medium-vessel occlusion, thrombectomy within 12 hours did not lead to a better functional outcome and lower mortality at 90 days than usual care.
- Few procedures have gone through a decade of practice-changing clinical trials as impressive as thrombectomy for stroke. Beginning in 2015 with multiple trials showing a benefit with thrombectomy in early large-vessel occlusion, followed by the extended-window trials in 2018 and then the large core trials in 2023, it seemed that...
- In this trial involving 543 patients with stroke due to occlusion of medium or distal vessels, endovascular treatment within 24 hours after the onset of symptoms was not effective in improving functional outcome at 90 days.
- In adults with myasthenia gravis, treatment with intravenous inebilizumab, a CD19-specific monoclonal antibody, significantly improved function and reduced disease severity at 26 weeks.
- In this phase 3 trial involving participants with nonrelapsing secondary progressive multiple sclerosis, treatment with tolebrutinib resulted in a lower risk of disability progression than placebo.
- In two trials in relapsing multiple sclerosis, tolebrutinib (a brain-penetrant BTK inhibitor) was not superior to teriflunomide at reducing annualized relapse rates.
- In patients with posterior circulation stroke for whom thrombectomy was not planned, alteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days than standard treatment.
- In a randomized trial, the routine use of cerebral embolic protection during TAVI did not reduce the incidence of stroke within 72 hours or before discharge from the hospital (if discharge occurred sooner).
- In a trial involving patients with subarachnoid hemorrhage and anemia, liberal transfusion of red cells did not result in a lower risk of an unfavorable neurologic outcome than a more restrictive strategy.
- The alternate splicing small molecule risdiplam, administered to a fetus with spinal muscular atrophy, had an apparent ameliorating effect on the disorder through 30 months.
- A 57-year-old woman presented with a 3-day history of altered mental status. Three weeks earlier, fever, weakness, cough, and diarrhea had developed, followed by intermittent visual hallucinations, tremors, and unsteadiness.
- Nonacute subdural hematoma is common among older persons. With an aging population and increasing use of antiplatelet and anticoagulant agents, subdural hematoma is projected to become the most common cranial neurosurgical disease by 2030.1 Standard treatments — including glucocorticoids and statins for milder cases, with the addition of...
- Among patients receiving surgical or nonsurgical standard treatment for chronic subdural hematoma, adjunctive middle meningeal artery embolization reduced the risk of treatment failure within 180 days.
- Mr. M. was notorious, and he’d managed to antagonize nearly everyone who cared for him each time he appeared at the hospital. How was a clinician supposed to find the requisite empathy in cases like his?
- The FDA often exercises flexibility in deciding whether to approve highly promising drugs for patients in desperate need of treatment options. But it doesn’t consider a drug’s likely financial toxicity.
- Maternal platelet-activating anti–platelet factor 4 antibodies led to cerebral venous sinus thrombosis, thrombocytopenia, hyperfibrinolysis, and cerebral bleeding in a neonate.